Cargando…

Risk of cardiac implantable device malfunction in cancer patients receiving proton therapy: an overview

Age is a risk factor for both cardiovascular disease and cancer, and as such radiation oncologists frequently see a number of patients with cardiac implantable electronic devices (CIEDs) receiving proton therapy (PT). CIED malfunctions induced by PT are nonnegligible and can occur in both passive sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirzaei, Milad, Rowshanfarzad, Pejman, Gill, Suki, Ebert, Martin A., Dass, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352826/
https://www.ncbi.nlm.nih.gov/pubmed/37469405
http://dx.doi.org/10.3389/fonc.2023.1181450
_version_ 1785074593087619072
author Mirzaei, Milad
Rowshanfarzad, Pejman
Gill, Suki
Ebert, Martin A.
Dass, Joshua
author_facet Mirzaei, Milad
Rowshanfarzad, Pejman
Gill, Suki
Ebert, Martin A.
Dass, Joshua
author_sort Mirzaei, Milad
collection PubMed
description Age is a risk factor for both cardiovascular disease and cancer, and as such radiation oncologists frequently see a number of patients with cardiac implantable electronic devices (CIEDs) receiving proton therapy (PT). CIED malfunctions induced by PT are nonnegligible and can occur in both passive scattering and pencil beam scanning modes. In the absence of an evidence-based protocol, the authors emphasise that this patient cohort should be managed differently to electron- and photon- external beam radiation therapy (EBRT) patients due to distinct properties of proton beams. Given the lack of a PT-specific guideline for managing this cohort and limited studies on this important topic; the process was initiated by evaluating all PT-related CIED malfunctions to provide a baseline for future reporting and research. In this review, different modes of PT and their interactions with a variety of CIEDs and pacing leads are discussed. Effects of PT on CIEDs were classified into a variety of hardware and software malfunctions. Apart from secondary neutrons, cumulative radiation dose, dose rate, CIED model/manufacturer, distance from CIED to proton field, and materials used in CIEDs/pacing leads were all evaluated to determine the probability of malfunctions. The importance of proton beam arrangements is highlighted in this study. Manufacturers should specify recommended dose limits for patients undergoing PT. The establishment of an international multidisciplinary team dedicated to CIED-bearing patients receiving PT may be beneficial.
format Online
Article
Text
id pubmed-10352826
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103528262023-07-19 Risk of cardiac implantable device malfunction in cancer patients receiving proton therapy: an overview Mirzaei, Milad Rowshanfarzad, Pejman Gill, Suki Ebert, Martin A. Dass, Joshua Front Oncol Oncology Age is a risk factor for both cardiovascular disease and cancer, and as such radiation oncologists frequently see a number of patients with cardiac implantable electronic devices (CIEDs) receiving proton therapy (PT). CIED malfunctions induced by PT are nonnegligible and can occur in both passive scattering and pencil beam scanning modes. In the absence of an evidence-based protocol, the authors emphasise that this patient cohort should be managed differently to electron- and photon- external beam radiation therapy (EBRT) patients due to distinct properties of proton beams. Given the lack of a PT-specific guideline for managing this cohort and limited studies on this important topic; the process was initiated by evaluating all PT-related CIED malfunctions to provide a baseline for future reporting and research. In this review, different modes of PT and their interactions with a variety of CIEDs and pacing leads are discussed. Effects of PT on CIEDs were classified into a variety of hardware and software malfunctions. Apart from secondary neutrons, cumulative radiation dose, dose rate, CIED model/manufacturer, distance from CIED to proton field, and materials used in CIEDs/pacing leads were all evaluated to determine the probability of malfunctions. The importance of proton beam arrangements is highlighted in this study. Manufacturers should specify recommended dose limits for patients undergoing PT. The establishment of an international multidisciplinary team dedicated to CIED-bearing patients receiving PT may be beneficial. Frontiers Media S.A. 2023-07-04 /pmc/articles/PMC10352826/ /pubmed/37469405 http://dx.doi.org/10.3389/fonc.2023.1181450 Text en Copyright © 2023 Mirzaei, Rowshanfarzad, Gill, Ebert and Dass https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Mirzaei, Milad
Rowshanfarzad, Pejman
Gill, Suki
Ebert, Martin A.
Dass, Joshua
Risk of cardiac implantable device malfunction in cancer patients receiving proton therapy: an overview
title Risk of cardiac implantable device malfunction in cancer patients receiving proton therapy: an overview
title_full Risk of cardiac implantable device malfunction in cancer patients receiving proton therapy: an overview
title_fullStr Risk of cardiac implantable device malfunction in cancer patients receiving proton therapy: an overview
title_full_unstemmed Risk of cardiac implantable device malfunction in cancer patients receiving proton therapy: an overview
title_short Risk of cardiac implantable device malfunction in cancer patients receiving proton therapy: an overview
title_sort risk of cardiac implantable device malfunction in cancer patients receiving proton therapy: an overview
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352826/
https://www.ncbi.nlm.nih.gov/pubmed/37469405
http://dx.doi.org/10.3389/fonc.2023.1181450
work_keys_str_mv AT mirzaeimilad riskofcardiacimplantabledevicemalfunctionincancerpatientsreceivingprotontherapyanoverview
AT rowshanfarzadpejman riskofcardiacimplantabledevicemalfunctionincancerpatientsreceivingprotontherapyanoverview
AT gillsuki riskofcardiacimplantabledevicemalfunctionincancerpatientsreceivingprotontherapyanoverview
AT ebertmartina riskofcardiacimplantabledevicemalfunctionincancerpatientsreceivingprotontherapyanoverview
AT dassjoshua riskofcardiacimplantabledevicemalfunctionincancerpatientsreceivingprotontherapyanoverview